unction of Abemaciclib

Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers.

Abemaciclib is a CD4/6 kinase inhibitor. This type of kinase is activated by connecting D-cyclin. In breast cancer cell lines that are estrogen receptor positive (HR+), cyclin D1 and CD4/ 6 It can bind to phosphorylation of retinoblastoma protein (Rb), cell cycle progression and cell proliferation. In vitro, continuous exposure to Abemaciclib inhibits Rb phosphorylation and prevents entry from G1 into the S phase of the cell cycle, leading to cell senescence and apoptosis. In breast cancer xenotransplantation models, Abemaciclib monotherapy or combined with anti-estrogens can be administered continuously every day to shrink tumors.

Application of Abemaciclib

Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers.